MADISON, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , is honored to announce that it received the "Best Management Team" and "Best Partnership Alliance" awards at the inaugural 2005 Scrip Awards Night and Gala Dinner in London.
"We are extremely proud to have received not one, but two, prestigious Scrip Awards," says Bernard Poussot, President, Wyeth Pharmaceuticals and Executive Vice President, Wyeth. "In an industry brimming with intelligence, innovation and an incomparable desire to deliver, it is truly an honor to be recognized as a leader."
Management Team of the Year
The "Management Team of the Year" award is bestowed upon a high-performance, model management team that effectively communicates a unified vision, demonstrates leadership amidst difficult times, and, in some cases, embraces an inter-disciplinary approach.
The Wyeth Research Discovery Review Board (DRB) Management Team, recognized as the "Management Team of the Year," is a cross-functional team responsible for the late discovery pipeline and delivering new compounds into development at Wyeth. Under the leadership of Frank Walsh, Ph.D., Executive Vice President and Head of Discovery Research, the team has demonstrated outstanding business performance and made significant contributions to R&D including, for example, maintaining an industry-leading productivity rate by moving 12 compounds per year into development since 2001 (averaging one new compound per month -- 60 compounds into development over the past 59 months).
Best Partnership Alliance
Judges evaluated nominations for the "Best Partnership Alliance" award by looking for those that were mutually beneficial to both parties, held promise to address an unmet medical need and demonstrated strategic potential as well as an innovative business model.
Schizophrenia and Alzheimer's disease represent tremendous scientific and medical challenges that prompted Wyeth Neuroscience Research, the Conway Institute at University College Dublin and Trinity College to partner to establish the Applied Neurotherapeutics Research Group (ANRG) in January 2004. ANRG was recognized as the "Best Partnership Alliance" as its structure and collaborative approach to research has enabled significant contributions to the Irish economy through intellectual property generation, educational opportunities and international industry recognition. Most importantly, the ANRG represents a true shared risk -- shared reward collaboration, which, in combination with the novel funding structure of this partnership makes it a truly innovative industry-academic collaboration.
About Scrip
Established in 1972, Scrip is the leading source of global business news in the pharmaceutical and biotechnology industries. Scrip is published by PJB Publications and can be found on the World Wide Web at http://www.pjbpubs.com.
About Wyeth
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the timing and success of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, wars or terrorist acts, product liability and other types of lawsuits, the impact of legislation and regulatory compliance and obtaining reimbursement, favorable drug pricing, access and other approvals, environmental liabilities, and patent, and other risks and uncertainties, including those detailed from time to time in the Company's periodic reports, including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
WyethCONTACT: Media, Gerald Burr of Wyeth Pharmaceuticals for Wyeth, +1-484-865-5138, or Douglas Petkus of Wyeth, +1-973-660-5218, or Investor, JustinVictoria of Wyeth, +1-973-660-5340
